[go: up one dir, main page]

CO5140118A1 - 4-SUBSTITUTED AND N-SUBSTITUTED PIPERIDINE SALTS - Google Patents

4-SUBSTITUTED AND N-SUBSTITUTED PIPERIDINE SALTS

Info

Publication number
CO5140118A1
CO5140118A1 CO99072637A CO99072637A CO5140118A1 CO 5140118 A1 CO5140118 A1 CO 5140118A1 CO 99072637 A CO99072637 A CO 99072637A CO 99072637 A CO99072637 A CO 99072637A CO 5140118 A1 CO5140118 A1 CO 5140118A1
Authority
CO
Colombia
Prior art keywords
alkyl
haloalkyl
hydrogen
independently
aralkyl
Prior art date
Application number
CO99072637A
Other languages
Spanish (es)
Inventor
Donald Roy Hirschfeld
Denis John Kertesz
David Bernard Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5140118A1 publication Critical patent/CO5140118A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto seleccionado de los compuestos de fórmula (I): <EMI FILE="99072637_1" ID="1" IMF=JPEG >en la que :uno de T y U es -N+R5- donde R5 es alquilo, haloalquilo, cianoalquilo, hidroxialquilo, alcoxialquilo, carboxialquilo, alcoxicarbonilalquilo, amidoalquilo, sulfonilaminoalquilo, o aralquilo y el otro es -CH-; X¯ es un anión farmacéuticamente aceptable; R1 y R2 son, independientemente uno de otro, hidrógeno o alquilo; m es un entero de 0 a 3 con la condición de que cuando T es -N+R5- entonces m es como mínimo 1; Ar y Ar1 son, independientemente uno de otro, arilo o heteroarilo; F es alquileno, alquenileno o un enlace; R es hidrógeno o alquilo; o R junto con bien R3 o R4 y los átomos a los que están unidos forman un carbociclo o un heterociclo; R3 y R4 son, independientemente uno de otro, hidrógeno, alquilo, alquenilo, haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, heterociclilo, heterociclilalquilo, heteroalquilo, o -(alquileno)-C(O)-Z donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, amino, amino mono sustituido con alquilo, heteroalquilo, haloalquilo, cicloalquilo, cicloalquilalquilo o fenilo opcionalmente sustituido independientemente con uno, dos o tres sustituyentes seleccionados de alquilo, haloalquilo, halo, nitro, ciano, -OR(donde R es hidrógeno o alquilo), -NRR´ (donde R y R´ son independientemente uno de otro hidrógeno o alquilo), -COOR (donde R es hidrógeno o alquilo) o -CONR´R" (donde R´ y R" son independientemente seleccionados de hidrógeno o alquilo); ó amino disustituido independientemente con alquilo, alquenilo, heteroalquilo, haloalquilo, cicloalquilo, cicloalquilalquilo o fenilo opcionalmente sustituido como se ha definido anteriormente; arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi; E es -C(O)N(R6)-, -S02N(R6)-, -N(R7)C(0)N(R6)-, -N(R7) S02N(R6)-, N(R7)C(S)N(R6)-, -N(R7)C(0)- o -N(R7)S02- donde; R6 y R7 son, independientemente uno de otro, hidrógeno, alquilo, acilo, haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, aralquenilo, heteroarilo, heteroaralquilo, heterocicloalquilo, heteroalquilo, o -(alquileno)-C(O)-Z, donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, - 2 -amino, amino mono- o disustituido como se ha definido anteriormente, arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi; Q es -CO- o una cadena de alquileno interrumpida opcionalmente por -C(O)-, -NR8, -O-, -S(O)0-2-, -C(O)N(R8)-, -N(R8)C(O)-, -N(R8)SO2-, -S02N(R8)-, -N(R9)C(O)N(R10)-, -N(R9)SO2N(R10)- o -N(R9)C(S)N(R10)- donde: R8, R9 y R10 son independientemente uno de otro, hidrógeno, alquilo, acilo, haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, aralquenilo, heteroarilo, heteroaralquilo, heterociclilalquilo, heteroalquilo, o -(alquileno)-C(O)-Z, donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, amino, amino mono- o disustituido como se ha definido anteriormente, arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi;y profármacos, isómeros individuales, mezclas de isómeros y sales farmacéuticamente aceptables de los mismos.A compound selected from the compounds of formula (I): <EMI FILE = "99072637_1" ID = "1" MFI = JPEG> in which: one of T and U is -N + R5- where R5 is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, amidoalkyl, sulfonylaminoalkyl, or aralkyl and the other is -CH-; X is a pharmaceutically acceptable anion; R1 and R2 are, independently of each other, hydrogen or alkyl; m is an integer from 0 to 3 with the proviso that when T is -N + R5- then m is at least 1; Ar and Ar1 are, independently of each other, aryl or heteroaryl; F is alkylene, alkenylene or a bond; R is hydrogen or alkyl; or R together with either R3 or R4 and the atoms to which they are attached form a carbocycle or a heterocycle; R3 and R4 are, independently of each other, hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, heteroalkyl, or - (alkylene) -C (O) -Z where Z it is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, amino mono substituted with alkyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl or phenyl optionally independently substituted with one, two or three substituents selected from alkyl, haloalkyl, halo, nitro, cyano, -OR (where R is hydrogen or alkyl), -NRR´ (where R and R´ are independently of each other hydrogen or alkyl), -COOR (where R is hydrogen or alkyl) or -CONR´R "(where R´ and R "are independently selected from hydrogen or alkyl); or amino independently disubstituted with alkyl, alkenyl, heteroalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl or phenyl optionally substituted as defined above; aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy; E is -C (O) N (R6) -, -S02N (R6) -, -N (R7) C (0) N (R6) -, -N (R7) S02N (R6) -, N (R7) C (S) N (R6) -, -N (R7) C (0) - or -N (R7) S02- where; R6 and R7 are, independently of each other, hydrogen, alkyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heteroalkyl, or - (alkylene) -C (O) -Z, where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, -2-amino, mono- or disubstituted amino as defined above, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy; Q is -CO- or an alkylene chain optionally interrupted by -C (O) -, -NR8, -O-, -S (O) 0-2-, -C (O) N (R8) -, -N (R8) C (O) -, -N (R8) SO2-, -S02N (R8) -, -N (R9) C (O) N (R10) -, -N (R9) SO2N (R10) - or -N (R9) C (S) N (R10) - where: R8, R9 and R10 are independently from each other, hydrogen, alkyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heterocyclylalkyl , heteroalkyl, or - (alkylene) -C (O) -Z, where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino as defined above, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy; and prodrugs, individual isomers, mixtures of isomers and pharmaceutically acceptable salts thereof.

CO99072637A 1998-11-20 1999-11-18 4-SUBSTITUTED AND N-SUBSTITUTED PIPERIDINE SALTS CO5140118A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10929398P 1998-11-20 1998-11-20

Publications (1)

Publication Number Publication Date
CO5140118A1 true CO5140118A1 (en) 2002-03-22

Family

ID=22326896

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99072637A CO5140118A1 (en) 1998-11-20 1999-11-18 4-SUBSTITUTED AND N-SUBSTITUTED PIPERIDINE SALTS

Country Status (20)

Country Link
US (1) US6342509B1 (en)
EP (1) EP1131290B1 (en)
JP (1) JP3421323B2 (en)
KR (1) KR20010081034A (en)
CN (1) CN1326440A (en)
AR (1) AR029151A1 (en)
AT (1) ATE386720T1 (en)
AU (1) AU1774600A (en)
BR (1) BR9915735A (en)
CA (1) CA2351631A1 (en)
CO (1) CO5140118A1 (en)
DE (2) DE69938193D1 (en)
ES (1) ES2158813B1 (en)
FR (1) FR2786179B1 (en)
GB (1) GB2343894B (en)
IT (1) IT1308657B1 (en)
PE (1) PE20001401A1 (en)
TR (1) TR200101397T2 (en)
WO (1) WO2000031033A1 (en)
ZA (1) ZA200103940B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1179341B1 (en) 1999-05-18 2005-11-09 Teijin Limited Remedies or preventives for diseases in association with chemokines
KR100667645B1 (en) 1999-08-04 2007-02-28 데이진 가부시키가이샤 Cyclic Amine Cr3 Antagonist
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
ES2527688T3 (en) 2000-09-29 2015-01-28 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
WO2002050064A1 (en) * 2000-12-19 2002-06-27 F. Hoffmann-La Roche Ag Substituted pyrrolidines as ccr-3 receptor antagonists
KR20040015191A (en) 2001-04-27 2004-02-18 미쯔비시 웰 파마 가부시키가이샤 Novel benzylpiperidine compound
GB0114699D0 (en) 2001-06-15 2001-08-08 Novartis Ag Organic compounds
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
AU2004215679A1 (en) * 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
SG131946A1 (en) * 2003-10-24 2007-05-28 Hoffmann La Roche Ccr3 receptor antagonists
SE0400208D0 (en) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
DK1801108T3 (en) 2004-09-08 2013-02-18 Mitsubishi Tanabe Pharma Corp Morpholine compounds for the treatment of inflammation.
ES2457041T3 (en) 2004-09-13 2014-04-24 Ono Pharmaceutical Co., Ltd. N-4-piperidylurea derivatives and medicines containing them as active ingredient
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
TW200738635A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200734305A (en) * 2005-08-02 2007-09-16 Astrazeneca Ab New salt III
PL1942108T3 (en) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Compound containing basic group and use thereof
DK1961744T3 (en) 2005-11-18 2013-07-15 Ono Pharmaceutical Co Compound containing basic groups and their use
BRPI0708731A2 (en) 2006-03-10 2011-06-07 Ono Pharmaceutical Co nitrogenous heterocyclic derivative, and pharmaceutical agent comprising the derivative as an active ingredient
JP5257068B2 (en) 2006-05-16 2013-08-07 小野薬品工業株式会社 Compound containing acidic group which may be protected and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
DE102008020746A1 (en) * 2008-04-25 2009-10-29 Saltigo Gmbh Process for the preparation of quaternary salts of piperidyl esters of mandelic acid
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
KR101180174B1 (en) 2010-04-23 2012-09-05 동아제약주식회사 Novel benzamide derivatives
JP6392344B2 (en) 2013-07-25 2018-09-19 ドン−ア エスティ カンパニー リミテッド Method for producing benzamide derivative, novel intermediate used in the production, and method for producing the intermediate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574418A (en) * 1976-11-16 1980-09-03 Anphar Sa Piperidine derivatives
US4163784A (en) * 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
DK159420C (en) 1983-03-09 1991-03-11 Ciba Geigy Ag N- (PIPERIDINYL-ALKYL) CARBOXAMIDES AND SALTS THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THE USE OF THE COMPOUNDS FOR THE PREPARATION OF ANTI-CYPOTIC PHARMACEUTICAL PREPARATIONS
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
DK623586A (en) 1985-12-27 1987-06-28 Eisai Co Ltd PIPERIDE INGREDIENTS OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
US4857330A (en) 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
CA2005741C (en) 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
JPH041128A (en) 1990-03-07 1992-01-06 Ajinomoto Co Inc Antiarrhythmic agent
US5143923B1 (en) 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
FR2677019B1 (en) 1991-05-27 1994-11-25 Pf Medicament NOVEL PIPERIDINES DISUBSTITUEES-1,4, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
US5438064A (en) * 1991-12-23 1995-08-01 American Home Products Corporation Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents
FR2688219B1 (en) 1992-03-03 1994-07-08 Sanofi Elf AMATONIUM QUATERNARY SALTS OF AMINO AROMATIC COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DK60893D0 (en) 1993-05-26 1993-05-26 Novo Nordisk As PIPERIDE INGREDIENTS, THEIR PREPARATION AND USE
AU6954194A (en) 1993-06-23 1995-01-17 Merrell Dow Pharmaceuticals Inc. Piperidin-1-yl-2,2-dialkylpropanonearylsulfonamide derivatives
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
EP0776324B1 (en) 1994-08-19 2002-06-12 Abbott Laboratories Endothelin antagonists
JPH0977742A (en) * 1995-09-12 1997-03-25 Kyorin Pharmaceut Co Ltd Novel benzamide derivative
CA2188485A1 (en) * 1995-11-17 1997-05-18 Ronald J. Mattson Piperidinylethylamide derivatives as serotonergic agents
GB9523526D0 (en) 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
JP4150435B2 (en) * 1996-04-18 2008-09-17 株式会社資生堂 Alkylene diamine derivatives and anti-ulcer agents, antibacterial agents
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
CA2261633A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AU2335699A (en) * 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
CA2350903A1 (en) 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Pyrrolidine derivatives-ccr-3 receptor antagonists
CA2346933A1 (en) 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
BR9915735A (en) 2001-09-04
GB9927228D0 (en) 2000-01-12
ATE386720T1 (en) 2008-03-15
JP2002530375A (en) 2002-09-17
ZA200103940B (en) 2002-08-15
ES2158813B1 (en) 2002-03-16
CA2351631A1 (en) 2000-06-02
PE20001401A1 (en) 2000-12-15
IT1308657B1 (en) 2002-01-09
GB2343894A (en) 2000-05-24
DE19955793A1 (en) 2000-05-25
GB2343894B (en) 2001-07-25
EP1131290B1 (en) 2008-02-20
WO2000031033A1 (en) 2000-06-02
EP1131290A1 (en) 2001-09-12
AR029151A1 (en) 2003-06-18
ITTO991021A0 (en) 1999-11-22
DE69938193D1 (en) 2008-04-03
KR20010081034A (en) 2001-08-25
FR2786179A1 (en) 2000-05-26
JP3421323B2 (en) 2003-06-30
ES2158813A1 (en) 2001-09-01
AU1774600A (en) 2000-06-13
ITTO991021A1 (en) 2001-05-22
US6342509B1 (en) 2002-01-29
TR200101397T2 (en) 2001-11-21
CN1326440A (en) 2001-12-12
FR2786179B1 (en) 2001-08-10

Similar Documents

Publication Publication Date Title
CO5140118A1 (en) 4-SUBSTITUTED AND N-SUBSTITUTED PIPERIDINE SALTS
AR016822A1 (en) A COMPOUND DERIVED FROM CYCLINE AMINE, ITS USE, A PROCESS FOR MANUFACTURING USEFUL COMPOUNDS TO MANUFACTURE IT, AND A COMPARISON PHARMACEUTICAL COMPOSITION
CO5140119A1 (en) 3-SUBSTITUTE-N- (IET) ARILALQUIL-PIRROLIDINAS
AR016009A1 (en) ISOTIAZOLCARBOXIAMIDAS, PROCEDURE FOR OBTAINING, COMPOSITIONS, YOUR EMPLOYMENT IN THE PROTECTION OF PLANTS AGAINST THE ATTACK BY INDESEABLE MICROORGANISMS, AND OF INSECTS, ARCKIDS AND NEMATODES, AND PROCEDURE FOR OBTAINING COMPOSITIONS
ES2196772T3 (en) AMINO CYCLES COMPOUNDS.
YU46803A (en) Heterocyclylalkyl piperidine derivatives, their preparation and compositions containing same
AR021995A1 (en) 1,2-ANELATED QUINOLINE DERIVATIVES.
AR036674A1 (en) INHIBITORS OF PHOSPHODIESTERASE V OF GUANINA OF POLICICLICOS, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT PHYSIOLOGICAL DISORDERS
CA2423103A1 (en) N-acylsulfonamide apoptosis promoters
ATE270103T1 (en) AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTIVE AGENTS
ES2259113T3 (en) INHIBITORS OF FACTOR XA AND OTHER SERINPROTEASES INVOLVED IN THE COAGULATION WATERFALL.
NO961655D0 (en) Certain fused pyrrole carboxanilides; a new class of GABA brain receptor ligands
AR061008A1 (en) INDOLOBENZAZEPINE HCV INHIBITORS FUSIONATED TO CYCLOPROPYL
NZ512731A (en) Tricyclic inhibitors of poly(ADP-ribose) polymerases
CO5271658A1 (en) CORTICOTROPINE RELEASE FACTOR ANTAGONISTS
ATE357142T1 (en) 7-AMINOTRIAZOLOPYRIMIDINES TO FIGHT HARMFUL FUNGALS
NZ307505A (en) Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
CO4980859A1 (en) ARILPIPERAZINES THAT HAVE ACTIVITY ON THE SEROTONINE RECEPTOR 1A
AR011425A1 (en) SULFAMIDE-DERIVED COMPOUNDS, THEIR USE, PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THEM AND A PROCEDURE FOR PREPARING SULFAMIDE-DERIVED COMPOUNDS
CO5170498A1 (en) BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
ES2194683T3 (en) NEW SILICATED DERIVATIVES OF N-SUBSTITUTED BENCIMIDAZOL-BENZAZOLES OR BEZOFURANIL-BENZAZOLES FILTERS; PHOTOPROTECTOR COSMETIC COMPOSITIONS CONTAINING AND USING THEM.
CO4990960A1 (en) 2-HALO-6-O SUBSTITUTED CETOLIDE DERIVATIVES
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.
DE602004019961D1 (en) USE OF 4-CYANONAPHTHALIN-1, 8-DICARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS FOR PROTECTING ORGANIC MATERIAL AGAINST THE DAMAGING EFFECTS OF LIGHT
PE20040750A1 (en) DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3